Fabry disease market value will reach $1.25 billion by 2024, report

The global treatment market for Fabry disease will expand in value from $683 million in 2014 to approximately $1.25 billion by 2024, driven primarily by rising physician awareness of the condition and consequently higher diagnosis rates, a new study finds.

According to research and consulting firm GlobalData’s latest report, this value increase, which will occur across the seven major markets (7MM) of the USA, France, Germany, Italy, Spain, UK, and Japan, represents a moderate compound annual growth rate (CAGR) of 6.3%.

Valentina Gburcik, GlobalData’s director of cardiovascular and metabolic disorders, says that alongside increasing diagnosed cases, the market entry of the first pharmacological chaperone for the treatment of Fabry disease, namely Amicus Therapeutics’ (Nasdaq: FOLD) migalastat, will also boost growth.